Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report)'s stock had its "overweight" rating restated by analysts at Cantor Fitzgerald in a research report issued on Friday, Benzinga reports.
AGIO has been the topic of a number of other research reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. The Goldman Sachs Group lifted their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a "neutral" rating in a research note on Tuesday, June 4th. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $51.33.
Read Our Latest Analysis on AGIO
Agios Pharmaceuticals Price Performance
Shares of Agios Pharmaceuticals stock traded up $0.09 during trading on Friday, hitting $47.47. The stock had a trading volume of 133,865 shares, compared to its average volume of 704,262. The business has a fifty day moving average of $45.69 and a two-hundred day moving average of $39.03. Agios Pharmaceuticals has a fifty-two week low of $19.80 and a fifty-two week high of $50.35. The firm has a market cap of $2.70 billion, a P/E ratio of -7.50 and a beta of 0.75.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts' consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.51) EPS. As a group, research analysts forecast that Agios Pharmaceuticals will post -4.85 earnings per share for the current year.
Insider Buying and Selling
In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the company's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is owned by insiders.
Institutional Investors Weigh In On Agios Pharmaceuticals
Hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $37,000. Quest Partners LLC bought a new position in Agios Pharmaceuticals during the second quarter valued at about $40,000. NEOS Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $210,000. North Star Asset Management Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $216,000. Finally, XTX Topco Ltd bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $230,000.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
